Check out our latest #whitepaper containing clinical trial data, real-world evidence, and example algorithms that detail how T2Candida can be incorporated into practice and improve care for invasive candidiasis in your own practice.
- March 31, 2023
Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes and cost. One of the major hurdles to effective sepsis management is the limitations of conventional diagnostics, which are blood-culture-based and take 1 to 5 or more days to identify sepsis-causing pathogens. Blood culture also misses 35-50% of infections altogether on the first blood draw and can be greatly affected by the presence of antimicrobials. These delays impact patient outcomes as one hour of delayed treatment increases mortality risk by nearly 8%.
To advance sepsis care, hospitals are turning to new technology that does not rely on blood culture. This year, six new peer-reviewed studies have been published on T2Direct Diagnostics, which provide blood culture-independent sepsis pathogen ID results in 3 to 5 hours. Due to improved detection, these studies from the U.S. and EU demonstrate that clinicians can achieve faster-targeted therapy, better outcomes, enhanced stewardship, and reduced cost of care. The T2Dx Instrument runs the first FDA-cleared tests to identify deadly sepsis-causing pathogens in whole blood: the T2Candida Panel and the now FDA-Cleared T2Bacteria Panel.